title: [Secondary prevention after acute coronary syndrome--role of modern drug therapy].
abstract: Treatment of acute coronary syndrome is under rapid progress. Nevertheless, the early complication rate remains high. Standard antithrombotic treatment is Aspirin 100 mg/d. Patients with elevated risk should be treated with Aspirin and Clopidogrel if primary invasive strategy ist not intended. Independent of the cholesterol level, statins should be given in the early phase of acute coronary syndrome. Dose adaptation is recommended after three months corresponding to the national guidelines. Mainly in diabetes mellitus, additional treatment with an ACE inhibitor lowers the overall cardiovascular risk also in patients without arterial hypertension or congestive heart failure. Six months after the acute event, risk stratification should be adapted.
authors.affiliation: Departement Innere Medizin, Kantonsspital, St. Gallen. walter.angehrn@kssg.ch
authors.forename: W
authors.initials: W
authors.lastname: Angehrn
mesh_terms: D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy*; D012008:Recurrence; D012307:Risk Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors